Podcasts about monoclonal antibodies

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a landscape teeming with strategic partnerships, groundbreaking clinical trial results, regulatory shifts, and innovative therapeutic approaches that are redefining patient care and drug development. Pfizer's monumental $10 billion collaboration with Innovent Biologics stands out as a testament to the shifting dynamics of the oncology sector. This partnership aims to develop 12 antibody-drug conjugate (ADC) and multispecific antibody programs, spotlighting these therapies' growing significance in oncology. The precision of antibodies in delivering cytotoxic agents directly to cancer cells offers a new frontier in minimizing collateral damage to healthy tissues—a crucial advancement in cancer treatment. The deal not only highlights Pfizer's commitment to expanding its oncology pipeline but also underscores the strategic importance of leveraging China's accelerated drug development ecosystem. In regulatory news, AstraZeneca's Imfinzi has garnered FDA approval for BCG-naive high-risk non-muscle-invasive bladder cancer. This milestone for PD-L1 inhibitors reflects the evolving landscape of immunotherapy. By harnessing monoclonal antibodies in combination therapies, the potential for enhanced anticancer efficacy is significant. With few therapeutic alternatives available, this approval presents a lifeline for many bladder cancer patients. Clinical trial outcomes also continue to capture attention. Eli Lilly's Nectin-4 targeting ADC showed promising results in advanced urothelial cancer, positioning itself as a potential competitor to Padcev. This innovation in ADC technology demonstrates the industry's relentless pursuit of targeted therapies that can revolutionize treatment paradigms. Bristol Myers Squibb's mezigdomide offers another example by showing a 52% reduction in progression risk for relapsed or refractory multiple myeloma patients, emphasizing the focus on addressing specific molecular pathways. In the realm of bispecific antibodies, Phanes Therapeutics' CLDN18.2/CD47 targeting therapy reported encouraging Phase 2 results in metastatic pancreatic ductal adenocarcinoma. These antibodies' ability to simultaneously engage multiple targets enhances their therapeutic efficacy against stubborn cancers, broadening the horizon for treatment possibilities. Meanwhile, Replimune's resubmission of its RP1 melanoma Biologics License Application (BLA) highlights the intricate dance between drug development and regulatory processes amid organizational shifts at the FDA. Such efforts reflect the continual adaptation required within the industry to navigate complex regulatory landscapes. On the funding front, Psilera's successful $8.8 million seed round indicates growing interest in psychedelic therapies for neurological conditions. Similarly, Reprogram Biosciences raised $6 million for its AI-driven cell reprogramming oncology platform, illustrating how artificial intelligence is becoming integral to advancing drug discovery and development. However, not all updates were positive. Agios Pharmaceuticals faced setbacks as their pyruvate kinase activator failed a Phase 2b trial for lower-risk myelodysplastic syndromes, serving as a sobering reminder of the inherent risks involved in drug development. Dizal Pharma emerges as a beacon of hope in lung cancer treatment following Takeda's EGFR exon 20 drug setback. By challenging existing treatments with promising small molecule data, Dizal exemplifies precision medicine's role in redefining oncology protocols—offering personalized patient options that could set new standards in treatment efficacy. The issue of drug pricing remains contentious, particularly highlighted by an AARP analysis showing an 81% increase post-launch prices stateside compared to a 13% decrease abroad. This disparity raises critical questions about achieving equitable access across markets amid Medicare negotiations and global pricing strategies like "most favored nation" policies. Regulatory updates continue with Johnson & Johnson's Tremfya label expansion stateside and AbbVie's EU extension for Venclyxto—moves that reflect efforts to maximize therapeutic reach and commercial viability across diverse geographies. Finally, Gilead Sciences' decision to discontinue its lead rheumatoid arthritis drug from MiroBio underscores ongoing challenges within emerging fields like BTLA agonists—a reminder of both innovation's promise and its perilous nature when faced with unproven therapeutic avenues. As these varied developments unfold, they collectively signal an era characterized by rapid scientific innovation and strategic collaborations across geographies alongside evolving regulatory landscapes—all driving towards enhanced patient care through more effective treatments globally. This concludes today's insights from Pharma Daily—a world where dynamic change continues reshaping healthcare delivery standards towards unprecedented possibilities for patient outcomes worldwide. Thank you for joining us; stay tuned for more updates on tomorrow's horizon-shaping advancements.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of events shaping the industry, ranging from regulatory hurdles to strategic acquisitions and scientific breakthroughs. A significant milestone has been achieved by Outlook Therapeutics with its product Lytenava (bevacizumab), which recently won an appeal with the FDA for wet age-related macular degeneration treatment. This antibody therapy, aimed at VEGF inhibitors, marks a notable advancement in ophthalmology, potentially transforming management strategies for this debilitating condition. Monoclonal antibodies like Lytenava continue to underscore their importance in treating chronic diseases, offering hope for patients and setting benchmarks for similar therapeutic innovations. On a less favorable note, AstraZeneca encountered a setback when their breast cancer treatment camizestrant faced rejection from an FDA advisory committee. Despite robust phase 3 data for hormone receptor-positive breast cancer, the advisory committee's decision delays the drug's review process. This serves as a stark reminder of the stringent requirements oncology treatments must meet and highlights the critical need for comprehensive clinical data to ensure patient safety and drug efficacy in this competitive field. Amidst these developments, Astellas is proactively addressing upcoming patent expirations, particularly for Xtandi in 2026. The company has announced a five-year growth strategy focused on pipeline acquisitions, illustrating broader industry trends where diversifying portfolios through acquisitions and partnerships is crucial for maintaining competitiveness and delivering innovative therapies. Business development activities continue to be a highlight within the sector. Apogee Therapeutics and Blackstone Life Sciences have entered into a $1.3 billion royalty financing agreement to advance an eczema drug, underscoring ongoing investments in autoimmune treatments. Similarly, AGC Biologics' partnership with Teikoku Seiyaku on microbial CDMO services aims at advancing musculoskeletal therapies, showcasing how collaborations can leverage specialized manufacturing capabilities for therapeutic progress. Clinical trials also made headlines as Junshi Biosciences reported that its drug toripalimab met primary endpoints in phase 3 trials for non-small cell lung cancer perioperative treatment. This achievement underscores the growing influence of immunotherapies in oncology, promising improved surgical outcomes and enhancing their role within cancer treatment paradigms. Funding continues to play a pivotal role in sustaining innovation within the industry. Editas Medicine recently raised $125 million to propel its CRISPR-based gene therapy pipeline forward. Such financial backing is instrumental in transitioning promising therapies from preclinical stages to market readiness, ensuring that groundbreaking science translates into patient-accessible treatments. Regulatory landscapes remain dynamic, with ongoing discussions about updating COVID-19 vaccine formulations to target emerging subvariants. The FDA's commitment to adapting vaccine guidelines reflects a proactive stance in infectious disease management, crucial for maintaining vaccine efficacy against evolving pathogens. In acquisition news, Olympus' purchase of Bioprotect for $270 million adds biodegradable balloon spacer technology to its prostate cancer radiation therapy offerings. This acquisition highlights how medical device innovations can complement pharmaceutical approaches, enhancing treatment efficacy and patient quality of life. These developments collectively paint a vibrant picture of the biotech and pharmaceutical industries—a landscape where scientific advancements, regulatory challenges, strategic planning, and financial investments converge. The implications are far-reaching, potentially redefining treatment paradigms across various therapeutic areas as these sectors continue their pursuit of innovation and improved patient care outcomes. Navigating this landscape also involves addressing broader challenges such as policy shifts and pricing pressures within key markets like the United States. Companies must remain adaptable, balancing growth strategies with compliance demands amidst changing regulatory environments—a theme echoed by recent surveys indicating heightened pressure on healthcare firms to maintain profitability. Moreover, geopolitical considerations are influencing cross-border investments in biotechnology as policymakers debate strategies best suited for managing foreign influence—reflecting broader concerns about national security and economic competitiveness within this critical sector. As we continue monitoring these dynamic shifts within pharmaceuticals and biotechnology, it's evident that scientific innovation remains tightly interwoven with regulatory scrutiny and financial dynamics. The ongoing dance between these elements will undoubtedly shape future trajectories in healthcare advancements globally, promising new horizons in patient care while addressing pressing health challenges worldwide. That's all for today's episode of Pharma Daily—where we keep you informed on the latest developments driving progress within pharmaceuticals and biotechnology. Thank you for tuning in; until next time!Support the show

Dr. Ron Elfenbein is an emergency physician and healthcare entrepreneur who found himself at the center of a high-stakes legal battle after being indicted on federal healthcare fraud charges. Maintaining his innocence, he mounted a determined fight against the allegations, challenging the government's case and drawing national attention to the complexities of medical billing, regulatory overreach, and due process in modern healthcare. In this episode, Drs. Brian and Ron talk about… (00:00) Intro (04:01) The miracle cure that Monoclonal Antibodies were for Covid patients and how the treatment was withheld from those who needed it most by the federal government (18:28) How Dr. Ron became a victim of Lawfare for his efforts to make monoclonal antibodies available to Covid patients (28:29) Dr. Ron's perspective on why he was targeted for championing monoclonal antibodies to treat Covid (31:24) Dr. Ron's ongoing legal battle (37:43) The pros and cons of using Remdesivir versus monoclonal antibodies to treat Covid patients (43:05) The financial disaster that has befallen Dr. Ron as a result of the federal inditement (47:18) The lives that were lost because of the Biden administration's inexplicable shut down of the monoclonal antibody treatment (50:58) Taking on the federal government in court (52:48) How you can support Dr. Ron's legal battle (links below) (56:28) Sauna (01:01:29) Outro   For more information, please see the links below. Thank you for listening!   Links:   Resources Mentioned in this Episode: Dr. Ron's last appearance on the Life's Best Medicine Podcast: https://lifesbestmedicine.com/podcast/episode-285-dr-ron-elfenbein/ Dr. Peter McCullough on the Life's Best Medicine Podcast: https://lifesbestmedicine.com/podcast/episode-281-dr-peter-mccullough/ Jessica Rose on the Life's Best Medicine Podcast: https://lifesbestmedicine.com/podcast/episode-282-dr-jessica-rose/   Dr. Ron Elfenbein: X: https://x.com/RonElfenbeinmd Website: Ronelfenbeinmd.com Support Doctor Elfenbein's Legal Defense: https://www.givesendgo.com/DefendDrElfenbein Change.org Petition: https://www.change.org/p/stop-the-lawfare-tell-the-doj-to-drop-the-unjust-prosecution-of-dr-ron-elfenbein?recruiter=1113307157&recruited_by_id=1ab998c0-a9bf-11ea-ab16-9f90afe15353&utm_source=share_petition&utm_campaign=petition_dashboard&utm_medium=copylink Judge's 93 Page Opinion: https://www2.mdd.uscourts.gov/Opinions/Opinions/22-0146%20Elfenbein%20Opinion.pdf Fox News Article: Maryland doctor says people are 'going to die' after Biden admin uses faulty data to snub antibody treatments Drop the Case: https://dropthecase.com   Dr. Brian Lenzkes:  Arizona Metabolic Health: https://arizonametabolichealth.com/ Low Carb MD Podcast: https://www.lowcarbmd.com/   HLTH Code: HLTH Code Promo Code: METHEALTH HLTH Code Website: https://gethlth.com

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic moves that are reshaping the landscape of drug development and patient care. In vaccine development, Sanofi has recently reported promising results from a comparative trial of its protein-based COVID-19 vaccine, Nuvaxovid, against Moderna's latest mRNA vaccine, MNEXspike. The focus here was primarily on tolerability, and Sanofi's candidate demonstrated a superior safety profile. This marks a significant moment in the ongoing evolution of vaccine technology, underscoring the importance of diversifying vaccine platforms to effectively address global public health challenges. Shifting to regulatory landscapes, the U.S. Food and Drug Administration has been tasked with expediting the review process for psychedelic drugs under a directive from former President Donald Trump. This move aims to enhance access to novel treatments for serious mental health conditions, reflecting a broader trend in medicine towards exploring therapeutic avenues beyond traditional pharmaceuticals. It highlights an increasing openness to alternative therapies that could potentially transform mental health care. Strategic acquisitions continue to fuel innovation within the sector. Eli Lilly's acquisition of Kelonia Therapeutics for up to $7 billion is particularly noteworthy. This investment marks Lilly's second venture into in vivo CAR-T technology this year, emphasizing its commitment to advancing cell-based therapies. Kelonia's work on phase 1-stage myeloma therapy showcases the potential of CAR-T modalities in treating complex diseases, promising expanded treatment options for patients. Globally, infrastructure development is gaining momentum with Biovac securing a $108 million finance package to establish Africa's first fully integrated vaccine production facility. This initiative is crucial for enhancing regional healthcare autonomy by addressing local health needs and reducing reliance on external supply chains—a step forward in building resilient healthcare systems. In oncology, Merck & Co. has unveiled clinical data for its PD-1xVEGF bispecific antibody in non-small cell lung cancer (NSCLC). The results reveal similar efficacy and safety profiles compared to existing treatments, suggesting promising prospects for this bispecific approach in oncology therapeutics. Bispecific antibodies are engineered to engage two different targets simultaneously, potentially enhancing anti-tumor efficacy by not only stimulating immune responses but also disrupting angiogenesis. This innovation represents a continued focus on targeted cancer therapies that enhance treatment precision. Similarly, AstraZeneca's IL-33 inhibitor has achieved another phase 3 success in treating chronic obstructive pulmonary disease (COPD). This reinforces the therapeutic potential of targeting interleukin pathways in inflammatory diseases and reflects AstraZeneca's strategic focus on respiratory conditions. Such successes highlight the promise of precision medicine in improving patient outcomes. On the topic of market expansion, GlaxoSmithKline's multiple myeloma treatment Blenrep has entered the Chinese market. This move exemplifies the growing importance of global market access strategies, ensuring that patients worldwide can benefit from cutting-edge therapies. Now let's turn our attention to some intriguing scientific developments. A former Genentech leader has launched a synthetic design lab focused on adaptive "smart" antibody-drug conjugates (ADCs) for cancer therapy. ADCs represent a significant leap forward in precision medicine by offering targeted cancer treatments that minimize damage to healthy cells. These "smart" ADCs could provide more effective and less toxic options for cancer patients. Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a fascinating realm where technology and biology converge, starting with a deepening relationship between biopharma and artificial intelligence. Novartis CEO Vas Narasimhan's recent appointment to the board of AI company Anthropic signals the strategic integration of AI into drug discovery and development processes. This collaboration highlights a growing trend where pharmaceutical companies are increasingly leveraging AI to optimize clinical trials, streamline drug discovery, and personalize patient care strategies. Similarly, Novo Nordisk has announced a strategic partnership with OpenAI to integrate AI technologies across various facets of its operations, including drug discovery and manufacturing. By leveraging OpenAI's machine learning capabilities, Novo Nordisk aims to streamline research efforts and accelerate therapeutic identification—a collaboration reflecting AI's growing role as an essential tool for maintaining competitiveness in drug development. Additionally, Amazon Web Services' launch of the Amazon Bio Discovery AI tool marks another milestone. Designed to expedite antibody design and drug discovery processes, it provides researchers with robust AI-driven platforms enhancing therapeutic design speed and accuracy. The emphasis on monoclonal antibodies aligns with industry trends focusing on targeted therapies for diseases such as cancer. Meanwhile, Eli Lilly's new obesity treatment, Foundayo, has caught the FDA's attention due to potential safety concerns. Despite progressing with its launch, the FDA has requested additional safety information to address unexpected serious risks associated with the drug. This highlights the ongoing regulatory scrutiny that accompanies novel treatments, especially in areas like obesity where patient populations are large and diverse. In another strategic move, Eli Lilly's acquisition of Crossbridge Bio for up to $300 million aims to bolster its oncology pipeline with dual-payload antibody-drug conjugates (ADCs). This acquisition reflects a strategic move enhancing Eli Lilly's position in oncology by integrating cutting-edge ADC technologies known for delivering cytotoxic agents directly to cancer cells while minimizing off-target effects. On another front, Travere Therapeutics is mapping a pathway to a potential $3 billion opportunity in the U.S. market following significant approval for its treatment Filspari, targeted at rare kidney diseases. This approval underscores the increasing focus on rare diseases, which present lucrative opportunities for pharmaceutical companies due to significant unmet needs and often high-cost treatments. Astellas' manufacturing strategy underscores the importance of reliable supply as a critical bridge from research to patient care. Led by Chief Manufacturing Officer Rao Mantri, this strategy highlights how manufacturing excellence can significantly impact drug availability and patient outcomes. It emphasizes that production reliability is vital in ensuring groundbreaking research translates into accessible medical treatments. In contrast, a slowdown in IPOs has been noted amidst an aggressive merger and acquisition spree by major pharmaceutical companies. This consolidation trend reflects strategic shifts within the industry as companies seek to bolster pipelines through acquisitions rather than organic growth. Such dynamics indicate a strategic pivot as firms prioritize acquiring promising assets over developing them from scratch. Ionis Pharmaceuticals' recent win in a drug naming competition exemplifies the complexities involved in branding within the pharmaceutical sector. Crafting a drug name that is memorable yet distinctive involves balancing marketability with regulatory requirements—a reflection of the intSupport the show

Send me a question or story!This is the last installment in our series of DERM DRUGS. Monoclonal antibodies are becoming an important tool in veterinary dermatology — but what are they, and how do they actually work?In this episode, we break down monoclonal antibody therapy in practical terms. We explain how these targeted treatments are designed to recognize and block specific molecules in the immune system, helping reduce itch in allergic dogs without broadly suppressing immunity.We discuss commonly used products like Cytopoint which targets IL-31, a key cytokine involved in pruritus. We also introduce the announcement of an upcoming (not yet released) product called Befrena, another monoclonal antibody therapy, and what we know about this therapy today.00:00 – Intro02:07 – What is a Monoclonal Antibody03:18 – Cytopoint Basics05:35 – Potential Side-Effects06:33 – Befrena Basics08:44 – Overview09:22 – Outro

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of these industries, exploring significant regulatory shifts, scientific breakthroughs, and strategic corporate maneuvers that are shaping the future of healthcare.The pharmaceutical and biotech sectors are currently navigating a period of profound transition. Recent regulatory developments have captured attention, particularly the U.S. Supreme Court's decision to overturn emergency tariffs imposed by the previous administration. This ruling is pivotal as it alleviates financial pressures on the industry, allowing companies to redirect their resources towards innovation and development. It underscores the interconnectedness of global supply chains and highlights the importance of stable regulatory environments for fostering industry growth.In a notable advancement within oncology, AstraZeneca has achieved FDA approval for its combination therapy of Calquence and Venclexta as an all-oral regimen for first-line chronic lymphocytic leukemia (CLL). This approval not only positions AstraZeneca competitively in the BTK inhibitor market but also signifies a shift towards more patient-friendly treatment regimens. By simplifying therapy, this development promises to enhance patient compliance and improve outcomes, challenging existing standards in CLL care.Meanwhile, internal challenges at the Centers for Disease Control and Prevention have led to a postponement of a critical vaccine advisory panel meeting. This delay occurs amid evolving vaccine policies that have sparked debate within the public health community, potentially impacting immunization strategies and initiatives aimed at bolstering public health.Corporate governance within the industry is also experiencing shifts. Novo Nordisk has nominated two industry veterans to its board as part of an ongoing strategy to align leadership with evolving business objectives. Similarly, Roche is contemplating divesting its once-blockbuster antibiotic Rocephin in response to competitive pressures from generics in Europe. These moves reflect a broader industry trend where companies are re-evaluating their portfolios to better respond to market dynamics and patent expirations.Novartis is making strategic changes as well by selling its stake in Novartis India Limited while maintaining separate commercial and R&D interests in the region. This action highlights a growing trend among pharmaceutical giants towards streamlining operations and focusing on high-growth areas—a strategy aimed at maximizing resource allocation efficiency.Despite narrowly missing a $1 billion revenue target for 2025, Madrigal Pharmaceuticals remains optimistic about the growth prospects of its drug Rezdiifra within the metabolic dysfunction-associated steatohepatitis (MASH) market. The company anticipates further expansion driven by unmet medical needs, underscoring the competitive dynamics within this therapeutic area.In personnel movements that could influence strategic directions, Daiichi Sankyo has appointed former Novartis CMO John Tsai as head of its R&D division. His expertise is expected to bolster Daiichi's focus on oncology and other critical therapeutic areas, potentially accelerating innovation within their drug development pipeline.Meanwhile, Manus Bio has secured a $15 million contract with the U.S. government for domestic supply of shikimic acid, an essential component for producing Tamiflu. This contract highlights efforts to strengthen domestic pharmaceutical supply chains amid global uncertainties—a crucial consideration for ensuring medication availability during crises.In clinical research, a setback was observed with Grail's Galleri cancer blood test trial failing to meet its primary endpoint in collaboration with the NHS. The resulting decline in GrailSupport the show

"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer.  Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article:  A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14  "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant shifts and advancements shaping these dynamic industries.Let's begin with Imvax, a biotechnology company that's making waves with its brain cancer cell therapy. Despite not hitting the primary endpoint in their Phase 2b trial, Imvax has taken the bold step of submitting their therapy to the FDA. This decision is rooted in the promising overall survival data observed during the trial. It highlights a growing trend where survival metrics are becoming critical indicators of a therapy's potential value. The company's pursuit of regulatory approval underscores an ongoing commitment within the industry to address challenging conditions like brain cancer with innovative treatment options.Meanwhile, Janux Therapeutics is facing its own set of challenges with its T-cell engager technology. Recent setbacks have led to a notable dip in stock value, yet analysts remain optimistic. The technology, despite current hurdles, holds promise for delivering best-in-class treatments. This situation reflects the inherent volatility and high stakes in biotech investments, where initial enthusiasm must be backed by consistent and robust clinical data to sustain market confidence.Tiziana Life Sciences is making strategic moves by spinning out its IL-6 drug into a separate entity. This decision comes amid heightened interest from major pharmaceutical players in the IL-6 pathway, known for its role in immune response modulation. The spinout strategy is part of a broader industry trend where companies are reorganizing their portfolios to focus on high-potential candidates that align with market demands and emerging scientific interests.Regulatory landscapes are also evolving with significant implications. The FDA's release of draft guidance aims to reduce primate testing for certain monoclonal antibodies, reflecting a broader ethical shift toward minimizing animal testing through alternative methods. This move aligns with global trends favoring more humane research methodologies and will likely influence how companies approach preclinical testing phases.In Europe, the EU's collaboration with Angelini Industries is injecting €150 million into health startups across the continent. This investment seeks to accelerate growth in digital health technologies, which are increasingly integral to modern healthcare solutions. Such funding initiatives are crucial for fostering innovation within Europe's biotech and medtech sectors.Across the Atlantic, legislative efforts in the United States are gaining momentum. The revival of the FDA's rare pediatric disease priority review voucher program highlights ongoing support for pediatric drug development. These vouchers incentivize treatments for rare diseases affecting children, addressing an area of unmet medical need that requires specific regulatory attention. This initiative has received unanimous support from Congress through the "Give Kids a Chance Act," underscoring a renewed commitment to treatments for rare pediatric diseases—a critical area where unmet medical needs persist due to limited commercial incentives.The FDA is also embracing cutting-edge technologies like agentic artificial intelligence (AI) to streamline its operations. AI tools have the potential to enhance decision-making efficiency and support more personalized medicine approaches, reflecting a commitment to integrating technology into regulatory processes.On the public health front, changes are underway as the CDC's Advisory Committee on Immunization Practices prepares to discuss updates on hepatitis B vaccines and childhood immunization schedules under new leadership. Such discussions are vital as they could shape future public health policies and vaccination strategies amid evolving data andSupport the show

Welcome to the Veterinary Breakroom! Join Alyssa Watson, DVM, and Beth Molleson, DVM, as they discuss pressing issues impacting the veterinary profession, including why monoclonal antibody therapies are poised to become one of the most important drug classes in both human and veterinary medicine. In this episode, they explore the mAbs already available in practice, where the pipeline is heading, and why staying informed matters for busy clinicians who want to be prepared for the next wave of therapeutic innovation.Contact:podcast@instinct.vetWhere To Find Us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/Instagram: @Clinicians.BriefX: @CliniciansBriefThe Team:Alyssa Watson, DVM - HostBeth Molleson, DVM - HostAlexis Ussery - Producer & Multimedia SpecialistDisclaimer: This podcast recording represents the opinions of Dr. Alyssa Watson and Dr. Beth Molleson. Content is presented for discussion purposes and should not be taken as medical advice. No guarantee is given regarding the accuracy of any statements or opinions made on the podcast.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about how monoclonal antibodies revolutionized neurologic treatment, why pregabalin link to increased heart failure, and a combined therapy that slows progression in primary progressive aphasia.

Respiratory syncytial virus (RSV) continues to pose a serious health threat—particularly to infants, older adults, and immunocompromised individuals—making it critical for pharmacy professionals to stay up to date on prevention and treatment options. This episode covers the latest FDA-approved RSV therapies, including vaccines and monoclonal antibodies, while highlighting clinical pearls for use across care settings. Tune in to stay informed and better support patients during the upcoming respiratory season.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTKalen Manasco, PharmD, BCPS, BCPPS, FCCP, FPPAProfessorUniversity of Florida College of PharmacyJoshua Davis Kinsey and Kalen Manasco have no relevant financial relationships with ineligible companies to disclose.  Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Differentiate between RSV vaccines and monoclonal antibody therapies, including their indications and target patient populations.2. Identify key counseling points and administration considerations associated with currently available RSV vaccines and monoclonal antibody therapies.0.05 CEU/0.5 HrUAN: 0107-0000-25-312-H01-PInitial release date: 11/3/2025Expiration date: 11/3/2026Additional CPE details can be found here.

Respiratory syncytial virus (RSV) continues to pose a serious health threat—particularly to infants, older adults, and immunocompromised individuals—making it critical for pharmacy professionals to stay up to date on prevention and treatment options. This episode covers the latest FDA-approved RSV therapies, including vaccines and monoclonal antibodies, while highlighting clinical pearls for use across care settings. Tune in to stay informed and better support patients during the upcoming respiratory season. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTKalen Manasco, PharmD, BCPS, BCPPS, FCCP, FPPAProfessorUniversity of Florida College of PharmacyJoshua Davis Kinsey and Kalen Manasco have no relevant financial relationships with ineligible companies to disclose. Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Differentiate between RSV vaccines and monoclonal antibody therapies, including their indications and target patient populations.2. Identify key counseling points and administration considerations associated with currently available RSV vaccines and monoclonal antibody therapies.0.05 CEU/0.5 HrUAN: 0107-0000-25-312-H01-PInitial release date: 11/3/2025Expiration date: 11/3/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant shifts and strategies shaping our industry.Novartis's acquisition of Avidity Biosciences for a staggering $12 billion marks a pivotal moment in the pharmaceutical landscape this year. With this acquisition, Novartis underscores its commitment to bolstering its neuromuscular disease pipeline. Avidity Biosciences has made a name for itself with its cutting-edge RNA therapeutic technologies, particularly its Antibody Oligonucleotide Conjugates (AOCs). This platform uniquely combines monoclonal antibodies with oligonucleotides, enhancing precision in targeting specific cell types. The integration of Avidity's technology into Novartis's research efforts could accelerate the development of new therapies, potentially transforming patient care with more effective and targeted treatment options. This move not only highlights the industry's focus on specialized therapeutic areas but also anticipates future advances in RNA therapeutics, extending beyond neuromuscular disorders to areas like oncology.In a similar vein, the FDA has shown its willingness to reconsider drugs that previously faced setbacks. GSK's Blenrep has made a return to the U.S. market after receiving approval for treating certain myeloma patients. This approval is particularly noteworthy given the drug's earlier negative advisory committee vote and postponed decision. It marks a significant rebound for GSK's oncology portfolio and reflects the FDA's dynamic approach towards drugs that show potential in specific therapeutic combinations.Meanwhile, Sanofi continues to make waves with Dupixent, achieving over €4 billion in quarterly sales due to its expanded indications. This success contrasts with a decline in Sanofi's vaccine sales, demonstrating shifting dynamics within pharmaceutical portfolios where biologics and specialty drugs are increasingly pivotal. Sanofi's recent financial report highlighted a notable 17% drop in vaccine sales due to reduced demand and pricing challenges in Europe. In response, companies must navigate fluctuating public health demands and economic pressures effectively.On the global stage, efforts to make transformative therapies like Vertex's Trikafta more accessible are gaining momentum through innovative trade-policy workarounds. A buyers club aims to introduce a lower-cost alternative produced by Bangladesh's Beximco, highlighting ongoing challenges and creative strategies in global drug accessibility.Roche's expansion through Chugai's $200 million M&A deal for an IgA nephropathy asset underscores the strategic importance of regional markets in driving growth. Similarly, Lonza's acquisition of a California biologics site aligns with its goals to meet increasing biomanufacturing demands.The industry is also adapting to technological advancements, with AI integration into life sciences commercialization being touted as a frontier for growth. Despite this potential, many organizations remain unprepared to harness AI fully. Leading companies embedding AI solutions aim for measurable outcomes that could significantly drive strategic decision-making and operational efficiencies.Eli Lilly's acquisition of Adverum Biotechnologies aligns with its strategic interests in gene therapy, focusing on promising therapeutic programs that address unmet medical needs. This acquisition centers around Ixo-vec for wet age-related macular degeneration (AMD), highlighting broader industry trends towards investing heavily in innovative therapies that address unmet needs.Conversely, Sanofi's halt on an RSV vaccine development highlights the inherent risks in vaccine development pipelines. Meanwhile, Regeneron's decision to discontinue a CAR T candidate acquired from 2seventy bio showcases ongoing reassessment witSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal changes and innovations shaping the industry landscape.Let's begin with a significant acquisition that is resonating across the sector. Alkermes has strategically acquired Avadel Pharmaceuticals for a noteworthy $2.1 billion. This acquisition is primarily aimed at Avadel's long-acting narcolepsy drug, Lumryz. This move not only acts as a growth catalyst for Alkermes but also strategically positions the company to potentially advance its own narcolepsy candidate, Alixorexton. This acquisition highlights a broader trend within the industry: a shift towards consolidation and specialization in niche therapeutic areas, reflecting the ongoing strategic maneuvering within the pharmaceutical sector to enhance therapeutic portfolios.In regulatory developments, there is an ongoing discussion around FDA cancer drug policies that's gaining attention. Eli Lilly's Oncology President has highlighted the need for clearer regulatory pathways. The debate revolves around whether to prioritize survival metrics without crossover incentives or encourage U.S. participation through crossover designs. This underscores a tension between maintaining regulatory rigor and offering flexibility in clinical trial design—a balance that impacts how quickly new oncology therapies can reach patients.Turning to international trade, there are significant movements as the Trump administration initiates a probe under Section 301 of the Trade Act of 1974. The aim is to assess if foreign nations are contributing their fair share to drug costs. Such an investigation could lead to tariffs, potentially altering global pharmaceutical trade dynamics and influencing international pricing strategies. Reports suggest that former President Donald Trump is exploring strategies to impose tariffs on U.S. trading partners not adequately compensating for pharmaceuticals, reflecting ongoing tensions regarding international drug pricing.Technology is revolutionizing life sciences commercialization strategies, with AI playing a pivotal role. Despite many organizations not being fully prepared for this digital shift, companies like Real Chemistry are pioneering AI applications to navigate regulatory complexities such as FDA marketing compliance. This digital transformation is set to redefine how pharmaceutical companies engage with patients and healthcare providers, enhancing efficiency and compliance.In legal news, Regeneron has settled a patent dispute with Celltrion over Eylea, allowing for the launch of a biosimilar by the end of 2026. This settlement is part of the growing biosimilars market, which offers cost-effective alternatives to high-priced biologics and enhances patient access to essential therapies.The industry's focus on oncology is further exemplified by Takeda's $1.2 billion upfront payment to Innovent Biologics for cancer assets. This deal includes substantial milestone payments, marking oncology as a key growth area post-Entyvio era and highlighting the high stakes associated with breakthrough cancer therapies. Continuing with significant industry maneuvers, Takeda Pharmaceuticals has announced a potential investment up to $11.4 billion to acquire three antibody-drug conjugates from Innovent Biologics. This deal includes an upfront payment of $1.2 billion and up to $10.2 billion in milestone payments—highlighting Takeda's commitment to expanding its oncology portfolio with innovative therapies that promise enhanced treatment outcomes for cancer patients.Ipsen's acquisition of ImCheck Therapeutics for $1.6 billion further emphasizes this focus on novel cancer treatments. The move includes ImCheck's mid-stage leukemia monoclonal antibody ICT01—an asset aimed at acute myeloid leukemia—indicating Ipsen's strategic push intSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant shifts occurring in these industries, touching on strategic restructuring, regulatory milestones, and groundbreaking scientific advancements that are shaping the future of drug development and patient care.Let's begin with a major corporate shakeup at Novo Nordisk. The company has announced a significant leadership transition as former CEO Lars Rebien Sorensen is set to become the new chairman of the board. This change follows the resignation of seven board members and indicates a strategic realignment within the company. The Novo Foundation's involvement suggests a deeper strategic shift, potentially aligning with new organizational objectives and innovations. Such moves are pivotal as they could influence Novo Nordisk's market position and future product development.Turning to scientific breakthroughs, Merck's collaboration with Kelun-Biotech has yielded promising results with their Trop2 antibody-drug conjugate, sacituzumab-tmt. This ADC has shown success in two Phase 3 trials targeting lung and breast cancers, underscoring the therapeutic potential of ADCs in oncology. By selectively targeting cancer cells while minimizing damage to healthy tissues, ADCs could significantly improve patient outcomes and represent a powerful modality in cancer treatment.In regulatory affairs, Kenvue is challenging the FDA over proposed safety warnings for Tylenol linked to autism during pregnancy. This dispute highlights the ongoing debates surrounding drug safety and regulatory oversight. The outcome could have significant implications for labeling practices and consumer trust in over-the-counter medications. Meanwhile, Summit Therapeutics plans to file for FDA approval of ivonescimab, highlighting ongoing innovation in drug development pipelines. Similarly, Novo Nordisk's semaglutide pill Rybelsus has received FDA expansion approval to reduce major adverse cardiovascular events. This sets a new benchmark for oral metabolism drugs by demonstrating their potential beyond glycemic control to positively impact cardiovascular health.As we explore industry trends, there's growing interest in direct-to-consumer drug sales. While this approach offers patients access to medications at reduced costs, it raises concerns about privacy and the quality of care without traditional healthcare provider interactions. Additionally, a notable decline in pharmaceutical TV ad spending by 19% in Q3 suggests a shift towards digital engagement strategies. Amidst these narratives, the Biotechnology Innovation Organization (BIO) has launched an awareness campaign to combat misinformation about vaccines. This effort underscores the importance of immunizations in public health and aims to reinforce trust amid rising disinformation.In another scientific advancement, GSK has released positive Phase 3 data for Spero Therapeutics' oral antibiotic candidate. The oral formulation's efficacy comparable to intravenous options could lead to broader use and improved patient adherence—critical advancements as antibiotic resistance remains a global health challenge.Investment activities reflect strategic shifts within the industry as well. Curewell Capital's investment in Wilmington PharmaTech aims to enhance U.S. active pharmaceutical ingredient production capacity—a crucial step given recent global supply chain disruptions. Similarly, India's ACG is making a $200 million investment in its first U.S. empty-capsule production facility, highlighting the strategic importance of manufacturing capabilities on American soil.Galapagos' decision to wind down its cell therapy unit marks a significant strategic pivot from its previous focus on this modality. This shift reflects broader industry trends where companies reassess priorSupport the show

Matters Microbial #109: Bat-Crazy About Rabies September 26, 2025 In honor of World Rabies Day, Dr. Rodney Rohde, Regents Professor at Texas State University,  joins the #QualityQuorum to discuss rabies and some of the strategies used to limit the influence of that devastating viral disease. Host: Mark O. Martin Guest: Rodney Rohde Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode An overview of rabies from the CDC. A historical overview of rabies and Louis Pasteur. The global impact of rabies. Bats and rabies. A podcast exploring rabies and myths about vampires and werewolves. A wonderful video about rabies SO worth your time. A video with three physicians about rabies. A detailed review of rabies and the rabies virus. The lifecycle of the rabies virus. Various tests for rabies. The vaccines for rabies. Rabies research at the CDC. Use of an oral rabies vaccine to eliminate epizootic rabies in coyotes and gray foxes in Texas. Information about World Rabies Day. The Contagion Live website, including podcasts by Dr. Rohde. A video from Dr. Rohde about medical laboratory science. A video from Dr. Rohde about rabies. Dr. Rohde's biography from the American Society for Microbiology. Dr. Rohde's faculty website. Dr. Rohde's personal website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

Episode 19 of onAIRR features a lively and insightful conversation with three outstanding scientists committed to advancing pandemic preparedness. Dr. Lauren Williamson and Dr. Robert Carnahan, both from Vanderbilt University Medical Center, and Dr. Matthew Vogt, from the University of North Carolina, share their passion for viral immunology and the art of discovering and developing therapeutic antibodies. onAIRR's guests provide a behind-the-scenes look at how collaborative research is shaping the future of global health. They introduce the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) research network, a major NIH-funded initiative aimed at strengthening pandemic readiness. The conversation explores the use of prototype pathogen approaches to identifying broadly neutralizing antibodies against high-priority viral families, the challenges of balancing breadth versus potency in therapeutic antibodies, and innovative screening methodologies that could transform our ability to respond to future pandemics. Comments are welcome to the inbox of onairr@airr-community.org or on social media under the tag #onAIRR. Further information can be found here: https://www.antibodysociety.org/the-airr-community/airr-c-podcast. The episode is hosted by Dr. Ulrik Stervbo and Dr. Zhaoqing Ding. Announcements and links Lauren Williamson https://www.vumc.org/crowe-lab/person/lauren-williamson-phd Robert Carnahan https://www.vumc.org/crowe-lab/person/robert-carnahan-phd Matthew Vogt https://www.vogtviruslab.com ReVAMPP  https://revampp.org ReVAMPP https://www.niaid.nih.gov/news-events/nih-awards-establish-pandemic-preparedness-research-network  "Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness” https://doi.org/10.1093/infdis/jiac296  Adaptive Immune Receptor Repertoire Community (AIRR-C) https://www.airr-community.org The Antibody Society (TAbS) https://www.antibodysociety.org AIRR-C Seminar Series https://www.antibodysociety.org/the-airr-community/airr-community-seminar-series

Report shows rapid declines in health of children and adolescents since 2007; N-acetylcysteine (NAC) for Parkinson's; Statins increase likelihood of hearing loss, tinnitus; Lithium orotate for Alzheimer's; Is tinnitus reversible? Novel implantable electrical vagus nerve stimulator approved for treatment of rheumatoid arthritis.

Medicare Advantage Minute announces 2019 statistics: 17% of MA claims were denied in that year but of those claims that were appealed, 57% were ultimately paid. In the "Your Medicare Benefits 2025" segment we learn how Medicare is likely to cover Monoclonal Antibodies when they are used for the treatment of early onset Alzheimer's disease. "Early onset" is described as symptoms appearing before age 65. Humana subsidiary CenterWell announced the purchase of bankrupt firm The Villages Health. Apparently they declared bankruptcy after discovering they owed hundreds of millions to Medicare. How does this sort of thing sneak up on a company? Finally, as alluded to in the headline of this episode, there was speculation about what might happen if a person insured by a High Deductible Medicare supplement. Would the family members tasked with paying the bills be burdened by extra accounting and check-writing duties in the event of a long period of disability? My answer? Unequivocally no! Contact me at: DBJ@MLMMailbag.com (Most severe critic: A+)                   Visit us on: BabyBoomer.ORG Inspired by: "MEDICARE FOR THE LAZY MAN 2025; Simplest & Easiest Guide Ever!" "MEDICARE DRUG PLANS: A SIMPLE D-I-Y GUIDE" For sale on Amazon.com. After enjoying the books, please consider returning to leave a short customer review to  help future readers. Official website: https://www.MedicareForTheLazyMan.com.

In this episode, Jonathan Sackier welcomes Claudio Cerchione, haematologist and researcher at the Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. From his early interest in plasma cell disorders, Cerchione shares key insights into the evolution of multiple myeloma (MM) research, the rising role of minimal residual disease (MRD), and promising developments in monoclonal antibodies and CAR-T therapy. He also reflects on standout moments from recent European Hematology Association (EHA) Congress and American Society of Clinical Oncology (ASCO) Annual Meeting, and shares his hopes for the future of haematology.   Timestamps: 2:14: Memorable career experiences for Claudio   4:20 Biggest breakthrough in MM  5:10 Interest in plasma cell disorders  6:30 A surprising fact about multiple myeloma  7:40 Claudio's top choice for a dinner party guest  10:30 The importance of MRD in haematology  13:00 Monoclonal antibodies and CAR-T therapies  19:00 Current challenges  22:22 Claudio's key EHA and ASCO takeaways  28:30 Claudio's three magic wishes  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.AbbVie's acquisition of Capstan Therapeutics for $2.1 billion highlights the increasing trend of mergers and acquisitions in the biopharmaceutical industry. This move gives AbbVie access to Capstan's novel in vivo CAR T therapy for autoimmune diseases. Meanwhile, Moderna's mRNA flu vaccine has shown promising results, outperforming the current standard shot in adults aged 50 and older. The FDA's deployment of an AI tool has sparked concerns regarding its readiness and legal implications.Following the approval of monoclonal antibodies for Alzheimer's disease, there has been a surge in deals related to research in this area. Wacker Biotech is now offering comprehensive biologics manufacturing services, covering everything from concept to commercialization.Additional updates cover various topics such as clinical trials progress, industry layoffs, and discussions on vaccine safety. Job opportunities within the biopharmaceutical sector are also available for those interested.

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Listen to the podcast here

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Download the transcript here

Cancer cells often have ways to hide from immune cells. Immunotherapy is a type of cancer treatment that helps our body's own defenses - "Natural Born Killers" - to more effectively fight the cancer. Learn how: https://bit.ly/3S5rAfAIn this Episode:01:37 - Relishing New York's Finer Moments04:47 - New York Cheesecake Recipe08:08 - Anna Quindlen - Gratitude for the Moments11:17 - Immunotherapy, How it Works and TypesCancer VaccinesCheckpoint InhibitorsT Cell TransferMonoclonal AntibodiesImmune System Modulators 21:58 - Discussion - Is this Pretty New?25:26 - Worn Hands28:31 - Outro#immunity #everydayisagift #cancervaccine #immunotherapy #tcelltherapy #checkpointinhibitors #monoclonalantibodies #immunesystemmodulators #newyorkcheesecake #cancertreatment #cancerchoices #cancertherapy Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

Jo Cheah talks to Bronwyn Jenkins, consultant neurologist, about the role of calcitonin gene-related peptide (CGRP)–targeted therapies in migraine treatment. Bronwyn explains the difference between tension-type headaches and migraines, and outlines current treatment options. The conversation also covers adverse effects, patient eligibility, and other important considerations for prescribers. Read the full article in Australian Prescriber.

Carrie Dougherty, MD, FAHS and Jessica Ailani, MD review migraine abstracts from the 2024 European Headache Congress.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-navigating-the-baseline-mri-for-anti-a-monoclonal-antibodies/27038/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

In this week's episode we'll learn more about the significance of hypercalcemia in monoclonal gammopathy of undetermined significance, the role of neutrophil gelatinase-associated lipocalin in hemostasis, and the feasibility of combining CD19-targeted NK- or T-cell therapy with anti-CD19 monoclonal antibodies.Featured Articles:Approaching Hypercalcemia in Gammopathy of Undetermined Significance: Insights from the iStopMM study Deficiency of neutrophil gelatinase-associated lipocalin elicits Hemophilia-like bleeding and clotting disorder Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis 

What are the downsides of pacemakers? Rethinking low-protein diets for chronic kidney disease; Bright light therapy and creatine alleviate depression; Withdrawal from World Health Organization assailed—but the U.S. can't afford to abdicate to its flawed dietary recommendations; Does a positive ANA blood test necessarily mean you're destined to develop an autoimmune disease? Unprecedented levels of sedative drug abuse among young people calls attention to “Anxious Generation."

The exorbitant cost of new drugs touted for psoriasis in direct-to-consumer ads highlights everything wrong with our medical system; When gastric bypass surgery sends blood sugar out of control; A campaign to ban ultra-processed foods from school meals may help alleviate nutritional threats to kids—but healthy eating begins at home; With winter viruses making the rounds, a remarkable supplement offers potent immune system support. 

Interview with Wei-Hsuan Lo-Ciganic, PhD, author of Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine. Hosted by Cynthia E. Armand, MD. Related Content: Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine

Interview with Wei-Hsuan Lo-Ciganic, PhD, author of Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine. Hosted by Cynthia E. Armand, MD. Related Content: Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine

In this episode, Jonathan sits down with Philip Smith to discuss groundbreaking advancements in gastroenterology, the impact of IBD research, and how his personal journey with Crohn's disease has influenced his career. From international guidelines to the role of digital platforms in healthcare, Smith offers a compelling insight into the future of gastrointestinal medicine.   Timestamps: (00:00)-Introduction (02:35)-Specialising in luminal gastroenterology (05:30)-IBD patient to practitioner (11:20)-Career highs and lows (17:40)-Smith's impactful IBD research (21:02)-The international approach to gastroenterology (25:39)-Screening colonoscopy (29:49)-Advancements and future priorities for IBD care (37:37)- Leveraging social media to engage with the gastroenterology community (43:30)-Identifying high-impact studies as EiC (49:06)-Three wishes for healthcare

In this episode, host Dr. Marc Dubin speaks with Dr. Peter Manes. They discuss the recently published Original Article: “Assessment of conflicts of interest in literature on monoclonal antibodies for chronic rhinosinusitis with nasal polyposis using the Open Payments Database”. The full manuscript is available online in the International Forum of Allergy and Rhinology. Listen […]

Dr Funmi Okunola MD interviews Professor Nancy Klimas MD about her research into the use of Monoclonal Antibodies as a possible treatment for Long COVID. We have an exciting and exclusive breaking news item in this episode!REFERENCES1 Scheppke KA, Pepe PE, Jui J, Crowe RP, Scheppke EK, Klimas NG, Marty AM. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: a report of signal index cases and call for targeted research. The American Journal of Emergency Medicine. 2024 Jan 1;75:122-7.2 Zuo W, He D, Liang C, Du S, Hua Z, Nie Q, Zhou X, Yang M, Tan H, Xu J, Yu Y. The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. The Lancet Infectious Diseases. 2024 Apr 22.3 Hope & Help for Fatigue and Chronic Illness - The Institute For Neuro-Immune Medicine Podcast4 Appelman B, Charlton BT, Goulding RP, Kerkhoff TJ, Breedveld EA, Noort W, Offringa C,Bloemers FW, van Weeghel M, Schomakers BV, Coelho P., Wüst Rob.C Muscle abnormalitiesworsen after post-exertional malaise in long COVID. Nature communications. 2024Jan 4;15(1):1-5

On this episode of Health 411, host Dr. Jonathan Karp and student producer Marina JB Are joined by Dr. Riggs, professor of Immunology at Rider University!

Alongside Cochrane Reviews of the effects of original drugs for the treatment of some diseases, reviews are starting to appear of the effects of biosimilars for these drugs. In this podcast, Roses Parker, Cochrane's Commissioning Editor tells us about the evidence in one of these reviews, published in November 2024, which considers biosimilar monoclonal antibodies for the treatment of patients with cancer.

Alongside Cochrane Reviews of the effects of original drugs for the treatment of some diseases, reviews are starting to appear of the effects of biosimilars for these drugs. In this podcast, Roses Parker, Cochrane's Commissioning Editor tells us about the evidence in one of these reviews, published in November 2024, which considers biosimilar monoclonal antibodies for the treatment of patients with cancer.

Join pediatrician Rachel Schultz, DO and Ob/Gyn Renda Knapp, MD as they discuss the RSV vaccine for babies and pregnant women. Why is this vaccine important? What is the difference between the vaccine for babies and the one for women? Learn about why RSV is dangerous for babies in particular.

RSV stands for respiratory syncytial virus, a common respiratory virus that usually causes upper respiratory illness with mild, cold-like symptoms. For some groups, like infants, RSV can be a severe lower respiratory tract illness. With no licensed vaccine available for babies, there are two options for protection against RSV. One option is a maternal RSV vaccine during pregnancy between 32 and 37 weeks from September through January. The other option is monoclonal antibodies administered to newborns within a week after birth. The vaccine and antibodies for RSV are both relatively newly approved treatments. This episode examines the available research to evaluate the safety and efficacy of these options so you can make an informed decision for yourself and your baby.     Thank you to our sponsors   Zahler goes above and beyond to use high-quality bioavailable ingredients like the active form of folate, bioavailable iron, and omega 3s. The Zahler Prenatal +DHA is my #1 recommendation for a high-quality prenatal vitamin.In October 2024, you can save 40% off the Zahler Prenatal +DHA on Amazon with the code PREPOD40. You can always see the current promo code for the Zahler prenatal vitamin by clicking here.   Try AG1 and get a FREE 1-year supply of immune-supporting Vitamin D AND 5 FREE AG1 travel packs with your first purchase. That's a $48 value for FREE! Just one daily scoop provides whole-body benefits like gut, immune, and stress support. AG1 sources bioavailable ingredients that actually work with your body. Plus, their formula has all non-GMO ingredients and contains no added sugar. With AG1, I know I am filling any nutrient gaps and supporting my gut for healthy digestion. (As a friendly reminder, pregnant or nursing women should seek professional medical advice before taking this or any other dietary supplement.)     Read the full article and resources that accompany this episode.      Join Pregnancy Podcast Premium to access the entire back catalog, listen to all episodes ad-free, get a copy of the Your Birth Plan Book, and more.     Check out the 40 Weeks podcast to learn how your baby grows each week and what is happening in your body. Plus, get a heads up on what to expect at your prenatal appointments and a tip for dads and partners.     For more evidence-based information, visit the Pregnancy Podcast website.

On this episode of Health 411, host Dr. Jonathan Karp and student producer Marina JB are joined by Professor of Biology and Behavioral Neuroscience at Rider University, Dr. Riggs. Tune in to learn about monoclonal antibodies, an important component of many medications and diagnostic processes!

We are BACK for SEASON FIVE of the pod! In this episode, Dr. Jessica Steier and Dr. Sarah Scheinman discuss Alzheimer's disease and cognitive decline. They cover essential topics including the definition and symptoms of Alzheimer's, the genetic and epigenetic basis of the disease, brain changes associated with Alzheimer's, risk factors such as age, genetics, and lifestyle, modifiable risk factors and prevention strategies, and current treatments and their controversies.The scientists emphasize that maintaining overall health is crucial for brain health. They recommend a combination of lifestyle choices that promote general well-being, which in turn support cognitive health.They explore various treatment options, including cholinesterase inhibitors, NMDA receptor antagonists, and monoclonal antibodies targeting amyloid beta. The conversation highlights the ongoing debates about treatment efficacy and the need for further research.The episode aims to provide valuable insights and alleviate fears surrounding Alzheimer's disease. It concludes with a rapid-fire Q&A segment addressing listeners' questions.All our sources from this episode are available at: https://www.unbiasedscipod.com/episodes/dont-you-forget-about-me-unraveling-alzheimers(00:01) Music and Season Five Welcome(04:30) Introducing Dr. Sarah Scheinman and the Topic of Alzheimer's(07:49) Understanding Alzheimer's Disease and Its Symptoms(10:50) The Genetic and Epigenetic Basis of Alzheimer's(18:23) Risk Factors for Alzheimer's: Age, Genetics, and Lifestyle(26:02) The Role of Amyloid Plaques and Tau Tangles in Alzheimer's(30:37) Promoting Early Diagnosis and Intervention for Alzheimer's(35:21) Breaking Down the Stigma and Building Scientific Literacy(41:51) Treatments for Alzheimer's Disease(46:27) Monoclonal Antibodies and Controversy(53:50) Diagnosing Alzheimer's Disease(55:32) Final Thoughts: Q&A: Common Questions About Alzheimer's DiseaseInterested in advertising with us? Please reach out to advertising@airwavemedia.com, with “Unbiased Science” in the subject line.PLEASE NOTE: The discussion and information provided in this podcast are for general educational, scientific, and informational purposes only and are not intended as, and should not be treated as, medical or other professional advice for any particular individual or individuals. Every person and medical issue is different, and diagnosis and treatment requires consideration of specific facts often unique to the individual. As such, the information contained in this podcast should not be used as a substitute for consultation with and/or treatment by a doctor or other medical professional. If you are experiencing any medical issue or have any medical concern, you should consult with a doctor or other medical professional.Further, due to the inherent limitations of a podcast such as this as well as ongoing scientific developments, we do not guarantee the completeness or accuracy of the information or analysis provided in this podcast, although, of course we always endeavor to provide comprehensive information and analysis. In no event may Unbiased Science or any of the participants in this podcast be held liable to the listener or anyone else for any decision allegedly made or action allegedly taken or not taken allegedly in reliance on the discussion or information in this podcast or for any damages allegedly resulting from such reliance. The information provided herein do not represent the views of our employers. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We are BACK for SEASON FIVE of the pod! In this episode, Dr. Jessica Steier and Dr. Sarah Scheinman discuss Alzheimer's disease and cognitive decline. They cover essential topics including the definition and symptoms of Alzheimer's, the genetic and epigenetic basis of the disease, brain changes associated with Alzheimer's, risk factors such as age, genetics, and lifestyle, modifiable risk factors and prevention strategies, and current treatments and their controversies. The scientists emphasize that maintaining overall health is crucial for brain health. They recommend a combination of lifestyle choices that promote general well-being, which in turn support cognitive health. They explore various treatment options, including cholinesterase inhibitors, NMDA receptor antagonists, and monoclonal antibodies targeting amyloid beta. The conversation highlights the ongoing debates about treatment efficacy and the need for further research. The episode aims to provide valuable insights and alleviate fears surrounding Alzheimer's disease. It concludes with a rapid-fire Q&A segment addressing listeners' questions. All our sources from this episode are available at: https://www.unbiasedscipod.com/episodes/dont-you-forget-about-me-unraveling-alzheimers (00:01) Music and Season Five Welcome (04:30) Introducing Dr. Sarah Scheinman and the Topic of Alzheimer's (07:49) Understanding Alzheimer's Disease and Its Symptoms (10:50) The Genetic and Epigenetic Basis of Alzheimer's (18:23) Risk Factors for Alzheimer's: Age, Genetics, and Lifestyle (26:02) The Role of Amyloid Plaques and Tau Tangles in Alzheimer's (30:37) Promoting Early Diagnosis and Intervention for Alzheimer's (35:21) Breaking Down the Stigma and Building Scientific Literacy (41:51) Treatments for Alzheimer's Disease (46:27) Monoclonal Antibodies and Controversy (53:50) Diagnosing Alzheimer's Disease (55:32) Final Thoughts: Q&A: Common Questions About Alzheimer's Disease Interested in advertising with us? Please reach out to advertising@airwavemedia.com, with “Unbiased Science” in the subject line. PLEASE NOTE: The discussion and information provided in this podcast are for general educational, scientific, and informational purposes only and are not intended as, and should not be treated as, medical or other professional advice for any particular individual or individuals. Every person and medical issue is different, and diagnosis and treatment requires consideration of specific facts often unique to the individual. As such, the information contained in this podcast should not be used as a substitute for consultation with and/or treatment by a doctor or other medical professional. If you are experiencing any medical issue or have any medical concern, you should consult with a doctor or other medical professional. Further, due to the inherent limitations of a podcast such as this as well as ongoing scientific developments, we do not guarantee the completeness or accuracy of the information or analysis provided in this podcast, although, of course we always endeavor to provide comprehensive information and analysis. In no event may Unbiased Science or any of the participants in this podcast be held liable to the listener or anyone else for any decision allegedly made or action allegedly taken or not taken allegedly in reliance on the discussion or information in this podcast or for any damages allegedly resulting from such reliance. The information provided herein do not represent the views of our employers. Learn more about your ad choices. Visit megaphone.fm/adchoices

—--

My book Reframe Your Brain, available now on Amazon https://tinyurl.com/3bwr9fm8 Find my "extra" content on Locals: https://ScottAdams.Locals.com Content: Politics, Climate Change Worries, Expert Distrust, ChatGPT George Floyd, AI Narrative Programming, Food Lobby Spending, Monoclonal Antibodies, Whole Food Diets, Working Moms Microdosing, Military Base Penetrations, Trump NYC Trial, Trump Libertarian Convention, Bitcoin Elizabeth Warren, Ross Ulbricht, Ana Navarro, RFK Jr., Hillary Clinton, Dave Chappelle, Half-pinion, Ron Brownstein, James Carville, Biden West Point, Hoax Debunking AI, Scott Adams ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ If you would like to enjoy this same content plus bonus content from Scott Adams, including micro-lessons on lots of useful topics to build your talent stack, please see scottadams.locals.com for full access to that secret treasure. --- Support this podcast: https://podcasters.spotify.com/pod/show/scott-adams00/support

This episode is for people who are seeking guidance about how we shall live and work and be joyful together in the face of on-going pandemic. Our guest is Dayna Nuckolls, known online as The People's Oracle, creator of the Divination For Liberation Framework of Sidereal Astrology and The 7 Essential Needs™️. Dayna is a multi-oracle diviner, musician, writer, speaker, and teacher. I'm so excited for her new project: The People's Public Health Education Campaign. We're talking about the pandemic, we're talking about liberatory astrology, we're planning for a future that includes a grassroots collective care renaissance. I hope I'll see you at the organizing meeting!  The People's Public Health Education Campaign Info Meeting Wednesday, April 3, 2024 at 6pm Central via Zoom Register to attend (or to receive meeting materials if you can't attend in person): https://bit.ly/pphec2024   For questions please contact Dayna on Insta @PeoplesOracle or James @jameslpoteet www.ThePeoplesOracle.com Follow Dayna on Instagram and Twitter: @PeoplesOracle YouTube: www.YouTube.com/LynnDayna Get the 2024 Sidereal Astrology Guide: https://shop.ThePeoplesOracle.com/collections/2024   Mentioned in this Episode   StatsCan Report, Dec 2023: Experiences of Canadians with long-term symptoms following COVID-19   Nature Medicine: Higher health risks associated with each Covid re-infection: Acute and postacute sequelae associated with SARS-CoV-2 reinfection   Mask blocs   Ba-Zi Chinese predictive astrology   Covid-19 Monoclonal Antibodies - emergency use authorization   How to Survive a Plague, by David France   Clean Air Club of Chicago   *** Leave feedback for the show!   Learn more about The Numinous Network   Sign up for my newsletter  

In a paradigm-shifting discovery, researchers uncovered that B cells, not T cells, wield significant influence on orchestrating neurological damage in MS. Join UCSF Professor Dr. Stephen Hauser as he shares the remarkable odyssey from hurdles to triumphs of developing B cell monoclonal antibody treatment for multiple sclerosis.  Disease impact, safety concerns and personalization of MS treatment of these medications including Ocrevus (ocrelizumab), Kesimpta (ofatumumab) and Briumvi (ublituximab) are highlighted.  Brain-penetrant BTK inhibitor therapies that may offer more direct targeting of B cells within the central nervous system, potentially unlocking new possibilities in treating progressive forms of MS. Professor Heinz Wiendl explores the connection between Epstein-Barr virus infection of B cells and the initiation and progression of MS including trials investigating strategies to target EBV-infected B cells. Pioneering approaches like CAR-T therapy and brain shuttle techniques provide optimism for the next generation of MS treatment. Barry Singer MD, Director of The MS Center for Innovations in Care, interviews:  Stephen Hauser MD, Professor of Neurology at the University of California, San Francisco (UCSF) and Director of the UCSF Weill Institute for Neurosciences Heinz Wiendl MD, Professor of Neurology and Chair of the Department of Neurology at the University Hospital of Muenster in Germany